GUANGZHOU INSTITUTES OF BIOMEDICINE AND HEALTH

A centre for stem cell and translational medicine in the Pearl River Delta

Just over a decade old, the Guangzhou Institutes of Biomedicine and Health is exploring new ways to combat disease through conducting vital research.

The Guangzhou Institutes of Biomedicine and Health (GIBH), Chinese Academy of Sciences, was established in 2003 by the Chinese Academy of Sciences, through collaborative agreements with the Guangdong and Guangzhou governments. The founders envisioned a modern institute with a forward-looking philosophy that would transform the research landscape of southern China. GIBH is realizing that vision, as evidenced by its gaining global recognition of its cutting-edge scientific research.

Strategic research
GIBH has become a first-rate organization with over 500 dedicated staff members and more than 300 graduate students. The scientists and students are currently engaging in five major fields of inquiry: stem cell biology, chemical biology, infection and immunity, public health and de novo drug discovery. The GIBH strategy combines both basic and translational research in focused areas. This strategy will not only provide a deep understanding of life and disease, but also catalyze breakthroughs in the diagnosis and treatment of illnesses. Based on this conviction, GIBH is devoting resources to developing cutting-edge technologies and to solving important scientific problems in a collaborative environment. Accordingly, GIBH is building a new state-of-the-art good-manufacturing-practice facility to manufacture clinical-grade cells, including neural stem cells and hepatocyte progenitor cells for human transplantation; these cells will be used to treat diseases of the central nervous system and liver, respectively.

Drug discovery
Over the years, GIBH has established a solid reputation through high-profile publications and the development of innovative drugs. For example, its innovative drug-discovery platform has advanced a number of clinical candidate drugs for the treatment of cancer and neural degenerative diseases. Two of its investigational new drugs were recently certified in 2016 by the Chinese Food and Drug Administration, allowing for the initiation of phase-one clinical trials in China. Its dual focus on original discovery and innovative applications will propel the organization towards even greater achievements in years to come.

Seeking collaborators
The overall vision of GIBH is to serve the citizens of China and the world through discovery. It is actively seeking external collaborations and partnerships with scientists and institutes where there is a mutual interest. GIBH offers commitment, creativity and opportunity. GIBH seeks individuals who share its vision and enthusiasm for the future. Positions are available at all ranks in five research programmes (for more information, visit http://www.gibh.cas.cn or http://english.gibh.cas.cn):

- Stem cell and regenerative medicine
- Chemistry and synthetic biology
- Infection and immunity
- Public health
- Drug discovery pipeline

Contact
E-mail: hr@gibh.org
Tel: 0086-20-32015342, 32015267
Fax: 0086-20-32015267
Address: 190 Kaiyuan Avenue, Science Park, Guangzhou, China, 510530

Advertiser retains sole responsibility for content